Penbrook Management’s Gilead Sciences GILD Stock Holding History

Penbrook Management’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-2,000	Closed	-$202K	–	107
2015 Q4	$202K	Buy	+2,000	New	+$208K	0.21%	101
2015 Q3	–	Sell	-3,000	Closed	-$351K	–	115
2015 Q2	$351K	Sell	3,000 -1,000	-25%	-$109K	0.33%	85
2015 Q1	$393K	Hold	4,000	–	–	0.35%	90
2014 Q4	$377K	Buy	4,000 +2,000	+100%	+$207K	0.34%	94
2014 Q3	$213K	Buy	+2,000	New	+$196K	0.2%	101
2014 Q2	–	Sell	-4,000	Closed	-$300K	–	120
2014 Q1	$300K	Hold	4,000	–	–	0.14%	102
2013 Q4	$300K	Buy	+4,000	New	+$279K	0.29%	85

Other funds holding GILD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Penbrook Management's GILD Position: Q1 2016 in Review

Penbrook Management sold out of Gilead Sciences (GILD) in Q1 2016, closing a stake of 2,000 shares — an estimated $202K sold.

Penbrook Management first reported a position in GILD in Q4 2013 and held it in 7 quarters. The position peaked at $393K in Q1 2015. 1,629 funds tracked by Wall St. Rank hold GILD as of Q1 2016.

Penbrook Management reported no remaining Gilead Sciences position as of Q1 2016 after selling out during the quarter.
Penbrook Management sold 2,000 Gilead Sciences shares in Q1 2016, an estimated $202K.
Penbrook Management first reported a position in Gilead Sciences in Q4 2013 and held it in 7 quarters.
Penbrook Management's Gilead Sciences position peaked at $393K in Q1 2015.
1,629 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2016.

Based on Penbrook Management's 13F filing for Q1 2016, filed 21 Apr 2016.